{
    "nct_id": "NCT06174987",
    "official_title": "A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)",
    "inclusion_criteria": "* Signed informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements.\n* Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition.\n* No evidence of progressive disease and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria\n* Participant who has been off T-DXd therapy for >18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study",
    "miscellaneous_criteria": ""
}